세계의 뇌졸중 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2035년)

Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

US $ 5,795 ￦ 7,939,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,050,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 16,160,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

뇌졸중 치료 시장 : 조사 범위

TMR의 조사 보고서 "세계 뇌졸중 치료 시장"은 2025-2035년의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2019년부터 2035년까지의 세계 뇌졸중 치료 시장의 수익과 예측을 제공하는데, 2025년을 기준 연도로, 2035년을 예측 연도로 삼고 있습니다. 또한, 2025-2035년 세계 뇌졸중 치료 시장의 CAGR%도 제시합니다.

본 보고서는 광범위한 1차 조사와 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 대상으로 한 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 문서 등을 참조하여 뇌졸중 치료 시장을 추정하는 2차 조사를 통해 작성되었습니다. 뇌졸중 치료 시장을 추론하였습니다.

시장 현황
2024년 시장 규모	39억 달러
2035년 시장 규모	94억 달러
CAGR	8.4%

이 보고서는 세계 뇌졸중 치료 시장의 경쟁 환경을 조사했습니다. 세계 뇌졸중 치료 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되어 있습니다. 기업 개요, 재무상태, 최근 동향, SWOT는 세계 뇌졸중 치료 시장에서 활동하는 주요 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 개요
• 시장 역학
• 세계의 뇌졸중 치료 시장 분석과 예측(2020년-2035년)

제5장 주요 인사이트

• 주요 업계 이벤트
• PESTEL 분석
• 주요 국가, 지역별 규제 시나리오
• Porter의 Five Forces 분석
• 제품/브랜드 분석
• 공급망 분석
• 파이프라인 분석

제6장 세계 시장 분석 및 예측 : 유형별

• 서론과 정의
• 주요 조사 결과와 발전
• 시장 매출 예측 : 유형별(2020년-2035년)
  • 허혈성 뇌졸중
    • 혈전성 뇌졸중
    • 색전성 뇌졸중
  • 출혈성 뇌졸중
    • 뇌내 출혈
    • 지주막하 출혈
• 시장의 매력 분석 : 유형별

제7장 세계 시장 분석 및 예측 : 약제 클래스별

• 서론과 정의
• 주요 조사 결과와 발전
• 시장 매출 예측 : 약제 클래스별(2020년-2035년)
  • 항응고제
  • 항혈소판제
  • 조직 플라스미노겐 활성화 인자(tPA)
  • 스타틴
  • 베타 차단제
  • 기타
• 시장의 매력 분석 : 약제 클래스별

제8장 세계 시장 분석 및 예측 : 투여 경로별

• 서론과 정의
• 주요 조사 결과와 발전
• 시장 매출 예측 : 투여 경로별(2020년-2035년)
  • 경구
  • 비경구
• 시장의 매력 분석 : 투여 경로별

제9장 세계 시장 분석 및 예측 : 약제 가용성별

• 서론과 정의
• 주요 조사 결과와 발전
• 시장 매출 예측 : 약제 가용성별(2020년-2035년)
  • 브랜드
  • 제네릭
• 시장의 매력 분석 : 약제 가용성 별

제10장 세계 시장 분석 및 예측 : 판매채널별

• 서론과 정의
• 주요 조사 결과와 발전
• 시장 매출 예측 : 유통 채널별(2020년-2035년)
  • 원내 약국
  • 소매 약국
  • 온라인 약국
• 시장의 매력 분석 : 유통 채널별

제11장 세계 시장 분석 및 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별(2020년-2035년)
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제12장 북미 시장 분석과 예측

제13장 유럽 시장 분석과 예측

제14장 아시아태평양 시장 분석과 예측

제15장 라틴아메리카 시장 분석과 예측

제16장 중동 및 아프리카 시장 분석과 예측

제17장 경쟁 구도

• 시장 기업 : 경쟁 매트릭스(기업 Tier별, 규모별)
• 시장 점유율 분석 : 기업별(2024년)
• 기업 개요
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche(Genentech)
  • Daiichi Sankyo Company, Limited
  • AstraZeneca
  • Biogen Inc.
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Mylan
  • Teva Pharmaceuticals
  • Zydus Cadila
  • Sun Pharmaceutical

LSH

영문 목차

영문목차

Stroke Treatment Market - Scope of Report

TMR's report on the global stroke treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global stroke treatment market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global stroke treatment market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the stroke treatment market.

Market Snapshot
Market Value in 2024	US$ 3.9 Bn
Market Value in 2035	US$ 9.4 Bn
CAGR	8.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global stroke treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global stroke treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global stroke treatment market.

The report delves into the competitive landscape of the global stroke treatment market. Key players operating in the global stroke treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global stroke treatment market profiled in this report.

Key Questions Answered in Global stroke treatment Market Report:

• What is the sales/revenue generated by stroke treatment across all regions during the forecast period?
• What are the opportunities in the global stroke treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Stroke Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global stroke treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global stroke treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global stroke treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Stroke Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Stroke Treatment Market Analysis and Forecast, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Key Industry Events
• 5.2. PESTEL Analysis
• 5.3. Regulatory Scenario by Key Countries/Regions
• 5.4. PORTER's Five Forces Analysis
• 5.5. Product/Brand Analysis
• 5.6. Supply Chain Analysis
• 5.7. Pipeline Analysis

6. Global Stroke Treatment Market Analysis and Forecast, by Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Type, 2020-2035
  • 6.3.1. Ischemic Stroke
    • 6.3.1.1. Thrombotic Stroke
    • 6.3.1.2. Embolic Stroke
  • 6.3.2. Hemorrhagic Stroke
    • 6.3.2.1. Intracerebral Hemorrhage
    • 6.3.2.2. Subarachnoid Hemorrhage
• 6.4. Market Attractiveness Analysis, by Type

7. Global Stroke Treatment Market Analysis and Forecast, by Drug Class

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Drug Class, 2020-2035
  • 7.3.1. Anticoagulants
  • 7.3.2. Antiplatelets
  • 7.3.3. Tissue plasminogen activator (tPA)
  • 7.3.4. Statins
  • 7.3.5. Beta-Blockers
  • 7.3.6. Others
• 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Stroke Treatment Market Analysis and Forecast, by Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Route of Administration, 2020-2035
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Stroke Treatment Market Analysis and Forecast, by Drug Availability

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Drug Availability, 2020-2035
  • 9.3.1. Branded
  • 9.3.2. Generic
• 9.4. Market Attractiveness Analysis, by Drug Availability

10. Global Stroke Treatment Market Analysis and Forecast, by Distribution Channel

• 10.1. Introduction & Definition
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by Distribution Channel, 2020-2035
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Stroke Treatment Market Analysis and Forecast, by Region

• 11.1. Key Findings
• 11.2. Market Value Forecast, by Region, 2020-2035
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness Analysis, by Region

12. North America Stroke Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Type, 2020-2035
  • 12.2.1. Ischemic Stroke
    • 12.2.1.1. Thrombotic Stroke
    • 12.2.1.2. Embolic Stroke
  • 12.2.2. Hemorrhagic Stroke
    • 12.2.2.1. Intracerebral Hemorrhage
    • 12.2.2.2. Subarachnoid Hemorrhage
• 12.3. Market Value Forecast, by Drug Class, 2020-2035
  • 12.3.1. Anticoagulants
  • 12.3.2. Antiplatelets
  • 12.3.3. Tissue plasminogen activator (tPA)
  • 12.3.4. Statins
  • 12.3.5. Beta-Blockers
  • 12.3.6. Others
• 12.4. Market Value Forecast, by Route of Administration, 2020-2035
  • 12.4.1. Oral
  • 12.4.2. Parenteral
• 12.5. Market Value Forecast, by Drug Availability, 2020-2035
  • 12.5.1. Branded
  • 12.5.2. Generic
• 12.6. Market Value Forecast, by Distribution Channel, 2020-2035
  • 12.6.1. Hospital Pharmacies
  • 12.6.2. Retail Pharmacies
  • 12.6.3. Online Pharmacies
• 12.7. Market Value Forecast, by Country, 2020-2035
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Type
  • 12.8.2. By Drug Class
  • 12.8.3. By Route of Administration
  • 12.8.4. By Drug Availability
  • 12.8.5. By Distribution Channel
  • 12.8.6. By Country

13. Europe Stroke Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Type, 2020-2035
  • 13.2.1. Ischemic Stroke
    • 13.2.1.1. Thrombotic Stroke
    • 13.2.1.2. Embolic Stroke
  • 13.2.2. Hemorrhagic Stroke
    • 13.2.2.1. Intracerebral Hemorrhage
    • 13.2.2.2. Subarachnoid Hemorrhage
• 13.3. Market Value Forecast, by Drug Class, 2020-2035
  • 13.3.1. Anticoagulants
  • 13.3.2. Antiplatelets
  • 13.3.3. Tissue plasminogen activator (tPA)
  • 13.3.4. Statins
  • 13.3.5. Beta-Blockers
  • 13.3.6. Others
• 13.4. Market Value Forecast, by Route of Administration, 2020-2035
  • 13.4.1. Oral
  • 13.4.2. Parenteral
• 13.5. Market Value Forecast, by Drug Availability, 2020-2035
  • 13.5.1. Branded
  • 13.5.2. Generic
• 13.6. Market Value Forecast, by Distribution Channel, 2020-2035
  • 13.6.1. Hospital Pharmacies
  • 13.6.2. Retail Pharmacies
  • 13.6.3. Online Pharmacies
• 13.7. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 13.7.1. Germany
  • 13.7.2. UK
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Type
  • 13.8.2. By Drug Class
  • 13.8.3. By Route of Administration
  • 13.8.4. By Drug Availability
  • 13.8.5. By Distribution Channel
  • 13.8.6. By Country/Sub-region

14. Asia Pacific Stroke Treatment Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Type, 2020-2035
  • 14.2.1. Ischemic Stroke
    • 14.2.1.1. Thrombotic Stroke
    • 14.2.1.2. Embolic Stroke
  • 14.2.2. Hemorrhagic Stroke
    • 14.2.2.1. Intracerebral Hemorrhage
    • 14.2.2.2. Subarachnoid Hemorrhage
• 14.3. Market Value Forecast, by Drug Class, 2020-2035
  • 14.3.1. Anticoagulants
  • 14.3.2. Antiplatelets
  • 14.3.3. Tissue plasminogen activator (tPA)
  • 14.3.4. Statins
  • 14.3.5. Beta-Blockers
  • 14.3.6. Others
• 14.4. Market Value Forecast, by Route of Administration, 2020-2035
  • 14.4.1. Oral
  • 14.4.2. Parenteral
• 14.5. Market Value Forecast, by Drug Availability, 2020-2035
  • 14.5.1. Branded
  • 14.5.2. Generic
• 14.6. Market Value Forecast, by Distribution Channel, 2020-2035
  • 14.6.1. Hospital Pharmacies
  • 14.6.2. Retail Pharmacies
  • 14.6.3. Online Pharmacies
• 14.7. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Type
  • 14.8.2. By Drug Class
  • 14.8.3. By Route of Administration
  • 14.8.4. By Drug Availability
  • 14.8.5. By Distribution Channel
  • 14.8.6. By Country/Sub-region

15. Latin America Stroke Treatment Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Type, 2020-2035
  • 15.2.1. Ischemic Stroke
    • 15.2.1.1. Thrombotic Stroke
    • 15.2.1.2. Embolic Stroke
  • 15.2.2. Hemorrhagic Stroke
    • 15.2.2.1. Intracerebral Hemorrhage
    • 15.2.2.2. Subarachnoid Hemorrhage
• 15.3. Market Value Forecast, by Drug Class, 2020-2035
  • 15.3.1. Anticoagulants
  • 15.3.2. Antiplatelets
  • 15.3.3. Tissue plasminogen activator (tPA)
  • 15.3.4. Statins
  • 15.3.5. Beta-Blockers
  • 15.3.6. Others
• 15.4. Market Value Forecast, by Route of Administration, 2020-2035
  • 15.4.1. Oral
  • 15.4.2. Parenteral
• 15.5. Market Value Forecast, by Drug Availability, 2020-2035
  • 15.5.1. Branded
  • 15.5.2. Generic
• 15.6. Market Value Forecast, by Distribution Channel, 2020-2035
  • 15.6.1. Hospital Pharmacies
  • 15.6.2. Retail Pharmacies
  • 15.6.3. Online Pharmacies
• 15.7. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Type
  • 15.8.2. By Drug Class
  • 15.8.3. By Route of Administration
  • 15.8.4. By Drug Availability
  • 15.8.5. By Distribution Channel
  • 15.8.6. By Country/Sub-region

16. Middle East & Africa Stroke Treatment Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Type, 2020-2035
  • 16.2.1. Ischemic Stroke
    • 16.2.1.1. Thrombotic Stroke
    • 16.2.1.2. Embolic Stroke
  • 16.2.2. Hemorrhagic Stroke
    • 16.2.2.1. Intracerebral Hemorrhage
    • 16.2.2.2. Subarachnoid Hemorrhage
• 16.3. Market Value Forecast, by Drug Class, 2020-2035
  • 16.3.1. Anticoagulants
  • 16.3.2. Antiplatelets
  • 16.3.3. Tissue plasminogen activator (tPA)
  • 16.3.4. Statins
  • 16.3.5. Beta-Blockers
  • 16.3.6. Others
• 16.4. Market Value Forecast, by Route of Administration, 2020-2035
  • 16.4.1. Oral
  • 16.4.2. Parenteral
• 16.5. Market Value Forecast, by Drug Availability, 2020-2035
  • 16.5.1. Branded
  • 16.5.2. Generic
• 16.6. Market Value Forecast, by Distribution Channel, 2020-2035
  • 16.6.1. Hospital Pharmacies
  • 16.6.2. Retail Pharmacies
  • 16.6.3. Online Pharmacies
• 16.7. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Type
  • 16.8.2. By Drug Class
  • 16.8.3. By Route of Administration
  • 16.8.4. By Drug Availability
  • 16.8.5. By Distribution Channel
  • 16.8.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 17.2. Market Share Analysis, by Company (2024)
• 17.3. Company Profiles
  • 17.3.1. Bristol-Myers Squibb Company
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. Sanofi
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. F. Hoffmann-La Roche (Genentech)
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. Daiichi Sankyo Company, Limited
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. AstraZeneca
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. Biogen Inc.
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. Johnson & Johnson Services, Inc.
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. Bayer AG
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Eli Lilly and Company
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. Mylan
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. Teva Pharmaceuticals
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments
  • 17.3.12. Zydus Cadila
    • 17.3.12.1. Company Overview
    • 17.3.12.2. Financial Overview
    • 17.3.12.3. Product Portfolio
    • 17.3.12.4. Business Strategies
    • 17.3.12.5. Recent Developments
  • 17.3.13. Sun Pharmaceutical
    • 17.3.13.1. Company Overview
    • 17.3.13.2. Financial Overview
    • 17.3.13.3. Product Portfolio
    • 17.3.13.4. Business Strategies
    • 17.3.13.5. Recent Developments

관련자료